Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted … – Yahoo Finance
Endpoints News |
Novartis announces first CAR–T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted …
Yahoo Finance CAR-T is different from typical small molecule or biologic therapies currently on the market because it is manufactured for each individual patient. During the treatment process, T cells are drawn from a patient's blood and reprogrammed in the … Novartis gets a speedy review for its CAR–T pioneer as FDA lines up a marketing decision Does the drama of the CAR–T race actually matter? FDA grants priority review to CTL019 for ALL |
